Biodistribution and pharmacokinetics of the 19F-labeled radiosensitizer 3-aminobenzamide: Assessment by 19F MR imaging

Magnetic Resonance Imaging

Volumn 23, Issue 9, 2005, Pages 967-976

  Brix, Gunnar ^a,b   Schlicker, Alexandra ^a   Mier, Walter ^a,c   Peschke, Peter ^a   Bellemann, Matthias E ^a,d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b BUNDESAMT FÜR STRAHLENSCHUTZ   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIVERSITY OF APPLIED SCIENCES JENA   (Germany)

Author keywords

3 Aminobenzamide; Drug targeting; Magnetic resonance imaging; R3327 AT1 prostate tumors; Radiosensitizer

Indexed keywords

3 AMINO N 2,2,2 TRIFLUOROETHYLBENZAMIDE; 3 AMINOBENZAMIDE; DRUG CARRIER; GADOLINIUM PENTETATE; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MONITORING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG UPTAKE; FLUORINATION; LIVER; LONGITUDINAL STUDY; MALE; MOUSE; MUSCLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSERVATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; QUANTUM YIELD; RAT; RISK ASSESSMENT; SAMPLING; SIGNAL DETECTION; SIGNAL NOISE RATIO; SPATIAL DISCRIMINATION; WHOLE BODY SCANNER;

ADENOCARCINOMA; ANIMALS; BENZAMIDES; FLUORINE RADIOISOTOPES; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RATS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 27944462205     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2005.09.003     Document Type: Article

References (36)

1. J.M. Brown Sensitizers and protectors in radiotherapy Cancer 55 1985 2222 2228
2. M.A. Shenoy, and B.B. Singh Chemical radiosensitizers in cancer therapy Cancer Invest 10 1992 533 551
3. C.J. McGinn, D.S. Shewach, and T.S. Lawrence Radiosensitizing nucleosides J Natl Cancer Inst 88 1996 1193 1203
4. V. Grégoire, W.N. Hittelman, J.F. Rosier, and L. Milas Chemo-radiotherapy: radiosensitizing nucleoside analogues Oncol Rep 6 1999 949 957
5. C.J. McGinn, and T.S. Lawrence Recent advances in the use of radiosensitizing nucleosides Semin Radiat Oncol 11 2001 270 280
6. B. Zackrisson, E. Kjellén, B. Glimelius, J. Carlsson, B. Littbrand, and I. Turesson Sensitizing and protective substances in radiation therapy and predictive assays Acta Oncol 41 2002 615 622
7. G.J. Southan, and C. Szabo Poly(ADP-ribose) polymerase inhibitors Curr Med Chem 10 2003 321 340
8. J.C. Ame, C. Spenlehauer, and G. de Murcia The PARP superfamily Bioessays 26 2004 882 893
9. W.M. Tong, U. Cortes, and Z.Q. Wang Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis Biochim Biophys Acta 1552 2001 27 37
10. Z. Herceg, and Z.Q. Wang Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death Mutat Res 477 2001 97 110
11. L.R. Kelland, K. Burgess, and G.G. Steel Differential radiosensitization by the poly(ADP-ribose) transferase inhibitor 3-aminobenzamide in human tumor cells of varying radiosensitivity Int J Radiat Oncol Biol Phys 14 1988 1239 1246
12. M. Fernet, V. Ponette, E. Deniaud-Alexandre, J. Ménissier-De Murcia, G. De Murcia, and N. Giocanti Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionizing radiation Int J Radiat Biol 76 2000 1621 1629
13. A. Chalmers, P. Johnston, M. Woodcock, M. Joiner, and B. Marples PARP-1, PARP-2, and the cellular response to low dose of ionizing radiation Int J Radiat Oncol Biol Phys 58 2004 410 419
14. L. Virág, and C. Szabó The therapeutic potential of poly(ADP-ribose)polymerase inhibitors Pharmacol Rev 54 2002 375 429
15. M.R. Purnell, and W.J. Whish Novel inhibitors of poly(ADP-ribose) synthetase Biochem J 185 1980 775 777
16. J.A. Smit, and J.H. Stark Inhibition the repair if DNA damage induced by gamma irradiation in rat thymocytes Radiat Res 137 1994 84 88
17. D. Mukhopadhyay, S. Anant, and S. Mukherji 3-Aminobenzamide delays rejoining of DNA stand breaks in γ-irradiated lymphocytes from patients with breast cancer and not cervical cancer Neoplasma 41 1994 151 157
18. A. Schlicker, P. Peschke, and A. Bürkle 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer Int J Radiat Biol 75 1999 91 100
19. 11C-labeled benzamide compounds of potential tracers for poly(ADP-ribose) synthetase Appl Radiat Isot 45 1994 707 714
20. 19F MR imaging Magn Reson Med 34 1995 302 307
21. 19F MR imaging Radiology 209 1998 259 267
22. 19F MR imaging Magn Reson Med 42 1999 936 943
23. J.T. Isaacs, W.B. Isaacs, and W.F. Feitz Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers Prostate 9 1986 261 281
24. L.R. Kelland, and K.S. Tonkin The effect of 3-aminobenzamide in the radiation response of three human cervix-carcinoma xenografts Radiother Oncol 15 1989 363 369
25. 19F imaging of 5-fluorouracil and α-fluoro-β- alanine Magn Reson Imaging 11 1993 1193 1201
26. S.A. Glantz Primer of biostatistics 4th ed. 1997 McGraw-Hill New York
27. H.B. Jijon, T. Churchill, D. Malfair, A. Wessler, L.D. Jewell, and H.G. Parsons Inhibition of poly(ADP-ribose)polymerase attenuates inflammation in a model of chronic colitis Am J Physiol Gastrointest Liver Physiol 279 2000 G641 G651
28. L. Liaudet, E. Szabo, L. Timashpolsky, L. Virag, A. Cziraki, and C. Szabo Suppression of poly(ADP-ribose)polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences Br J Pharmacol 133 2001 1424 1430
29. R.K. Jain Haemodynamic and transport barriers to the treatment of solid tumors Int J Radiat Biol 60 1991 85 100
30. R.K. Jain Delivery of molecular and cellular medicine to solid tumors Microcirculation 4 1997 1 23
31. J.M. Brown, and A.J. Giacchia The unique physiology of solid tumors: opportunities (and problems) for cancer therapy Cancer Res 58 1998 1408 1416
32. L.W. Seymour Passive tumor targeting of soluble macromolecules and drug conjugates Crit Rev Ther Drug Carrier Syst 9 1992 135 187
33. H. Sinn, H.H. Schrenk, and E.A. Friedrich Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I Int J Radiat Appl Instrum B 17 1990 819 827
34. U. Schilling, E.A. Friedrich, and H. Sinn Design of compounds having enhanced tumour uptake, using serum albumin as a carrier - Part II. In vivo studies Int J Radiat Appl Instrum B 19 1992 685 695
35. A. Schlicker, P. Peschke, and H. Sinn Albumin as a carrier system for delivering drugs to solid tumors PDA J Pharm Sci Technol 54 2000 442 448
36. S. Strieth, M.E. Eichhorn, and B. Sauer Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature Int J Cancer 110 2004 117 124